IGM Biosciences, Inc. IGMS
Set alert
1.27 0.00 0.00%
At close · Aug 14
1.27 Day range 1.27
6.15 52-week range 22.50
- YTD
- -79.21%
- 1 year
- -85.70%
- Open
- 1.27
- Prev close
- 1.27
- Mkt cap
- 387.11M
- Vol
- 1.59M
- Avg vol
- 268.09K
- EPS
- -3.61
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.27
- High
- 1.27
- Forward P/E
- -2.71
- Beta
- 0.19
- Short ratio
- 11.22
- Inst. own
- 63.97%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 12.15
- 200-d avg
- 10.57
- 1y target
- 19.73
2Y chart
Events in this range
- Mar 7, 2024Earnings: -1.01; estimate -1.06; surprise 4.72%
- May 8, 2024Earnings: —; estimate -0.84; surprise —%
- May 8, 2024Earnings: -0.83; estimate -0.84; surprise 1.19%
- Aug 14, 2024Earnings: -0.79; estimate 0.03; surprise -2733.33%
- Aug 14, 2024Earnings: —; estimate 0.03; surprise —%
- Oct 1, 2024Rating: RBC Capital · Outperform → Outperform
- Oct 1, 2024Rating: Wedbush · Outperform → Outperform
- Oct 1, 2024Rating: Guggenheim · Buy → Buy
- Oct 18, 2024Rating: RBC Capital · Outperform → Outperform
- Nov 8, 2024Earnings: -1.01; estimate -0.82; surprise -23.17%
- Nov 11, 2024Rating: Stifel · Buy → Buy
- Dec 6, 2024Rating: BMO Capital · — → Outperform
Signals (94)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Jul 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 2, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 13, 2025 | 1 year ago |
| SMA: Bearish | Jun 12, 2025 | 1 year ago |
| SMA: Bullish | May 23, 2025 | 1 year ago |
| SMA: Bearish | May 21, 2025 | 1 year ago |
| MACD: Buy Signal | May 20, 2025 | 1 year ago |
| SMA: Bullish | May 19, 2025 | 1 year ago |
| MACD: Sell Signal | May 7, 2025 | 1 year ago |
| SMA: Bearish | May 6, 2025 | 1 year ago |
| RSI: Oversold | Mar 18, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 28, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| RSI: Oversold | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 2, 2025 | 1 year ago |
| RSI: Oversold | Dec 27, 2024 | 1 year ago |
| RSI: Oversold | Dec 20, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 13, 2024 | 1 year ago |
| RSI: Oversold | Dec 13, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 2, 2024 | 1 year ago |
| RSI: Oversold | Nov 21, 2024 | 1 year ago |
| SMA: Bearish | Nov 14, 2024 | 1 year ago |
| RSI: Oversold | Nov 14, 2024 | 1 year ago |
| SMA: Bearish | Nov 6, 2024 | 1 year ago |
| MACD: Sell Signal | Nov 1, 2024 | 1 year ago |
| MACD: Buy Signal | Oct 25, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 24, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 22, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 1, 2024 | 2 years ago |
| RSI: Overbought | Sep 16, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 10, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bullish | Sep 9, 2024 | 2 years ago |
| SMA: Bearish | Sep 6, 2024 | 2 years ago |
| SMA: Bearish | Sep 6, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 6, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 21, 2024 | 2 years ago |
| SMA: Bullish | Aug 15, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Aug 9, 2024 | 2 years ago |
| SMA: Bearish | Aug 9, 2024 | 2 years ago |
| SMA: Bullish | Aug 8, 2024 | 2 years ago |
| SMA: Bullish | Aug 8, 2024 | 2 years ago |
| SMA: Bearish | Aug 7, 2024 | 2 years ago |
| SMA: Bearish | Aug 7, 2024 | 2 years ago |
| SMA: Bullish | Aug 6, 2024 | 2 years ago |
| SMA: Bullish | Aug 6, 2024 | 2 years ago |
| SMA: Bearish | Aug 2, 2024 | 2 years ago |
| SMA: Bearish | Aug 2, 2024 | 2 years ago |
| MACD: Sell Signal | Aug 1, 2024 | 2 years ago |
| RSI: Overbought | Jul 24, 2024 | 2 years ago |
| RSI: Overbought | Jul 15, 2024 | 2 years ago |
| SMA: Bullish | Jul 11, 2024 | 2 years ago |
| SMA: Bullish | Jul 11, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | May 29, 2024 | 2 years ago |
| MACD: Sell Signal | May 29, 2024 | 2 years ago |
| SMA: Bullish | May 22, 2024 | 2 years ago |
| MACD: Buy Signal | May 22, 2024 | 2 years ago |
| MACD: Sell Signal | May 20, 2024 | 2 years ago |
| SMA: Bearish | May 16, 2024 | 2 years ago |
| SMA: Bullish | May 15, 2024 | 2 years ago |
| SMA: Bearish | May 10, 2024 | 2 years ago |
| SMA: Bullish | May 9, 2024 | 2 years ago |
| SMA: Bearish | May 8, 2024 | 2 years ago |
| SMA: Bullish | May 3, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 25, 2024 | 2 years ago |
| RSI: Oversold | Apr 22, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 19, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 12, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 22, 2024 | 2 years ago |
| RSI: Overbought | Feb 16, 2024 | 2 years ago |
| RSI: Overbought | Feb 9, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 8, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 25, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 23, 2024 | 2 years ago |
| RSI: Overbought | Jan 23, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 17, 2024 | 2 years ago |
| RSI: Overbought | Jan 5, 2024 | 2 years ago |
| RSI: Overbought | Dec 28, 2023 | 2 years ago |
| RSI: Overbought | Dec 21, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 15, 2023 | 2 years ago |
| MACD: Sell Signal | Dec 13, 2023 | 2 years ago |
| SMA: Bullish | Nov 28, 2023 | 2 years ago |
| SMA: Bearish | Nov 22, 2023 | 2 years ago |
| SMA: Bullish | Nov 17, 2023 | 2 years ago |
| SMA: Bearish | Nov 16, 2023 | 2 years ago |
| SMA: Bullish | Nov 15, 2023 | 2 years ago |
| RSI: Oversold | Oct 27, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 26, 2023 | 3 years ago |
| RSI: Oversold | Oct 11, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 4, 2023 | 3 years ago |
Key statistics
- Market cap
- 387.11M
- Enterprise value
- 237.37M
- Trailing P/E
- 0.00
- Forward P/E
- -2.71
- PEG ratio
- 0.00
- Price / sales
- 132.66
- Price / book
- 4.90
- EPS (TTM)
- -3.61
- Beta
- 0.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.92M
- Revenue growth
- 1.40%
- Free cash flow
- -100.20M
- Total cash
- 218.79M
- Total debt
- 45.86M
- Return on equity
- -132.11%
- Shares outstanding
- 34.08M
- Short % of float
- 17.77%
- 50-day average
- 12.15
- 200-day average
- 10.57
Analyst view
Consensus: buy
Buy
Price target (mean) 19.73 +1453.3% upside
Now 1.27
- Target (low)
- 9.00
- Target (mean)
- 19.73
- Target (high)
- 48.00
Ratings (0m) 11 6 buy · 4 hold · 1 sell
- Strong buy2
- Buy4
- Hold4
- Sell0
- Strong sell1
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.785.
Financials — quick view
IGMS Revenue — quarterly 143.62M
IGMS Net income — quarterly 97.58M
IGMS EPS — quarterly 1.59
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.82 | -1.01 | -0.19 | -23.17% |
| Aug 14, 2024 | Jun 1, 2024 | 0.03 | -0.79 | -0.82 | -2,733.33% |
| Aug 14, 2024 | Jun 1, 2024 | 0.03 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.84 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -0.84 | -0.83 | +0.01 | +1.19% |
| Mar 7, 2024 | Dec 1, 2023 | -1.06 | -1.01 | +0.05 | +4.72% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 6, 2024 | BMO Capital | init | — | Outperform |
| Nov 11, 2024 | Stifel | main | Buy | Buy |
| Oct 18, 2024 | RBC Capital | main | Outperform | Outperform |
| Oct 1, 2024 | Guggenheim | main | Buy | Buy |
| Oct 1, 2024 | Wedbush | main | Outperform | Outperform |
| Oct 1, 2024 | RBC Capital | main | Outperform | Outperform |
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- igmbio.com
News
- IGM Biosciences, Inc. (IGMS) Q2 Earnings and Revenues Surpass Estimates
- IGMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of IGM Biosciences, Inc. is Fair to Shareholders
- IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right
- IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Misses Revenue Estimates
- IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
- Down -76.91% in 4 Weeks, Here's Why IGM Biosciences (IGMS) Looks Ripe for a Turnaround
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of IGM Biosciences, Inc. - IGMS
Your note
Sign in to keep a note on IGMS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Sep 29, 2024 | 0 |
| BEHRENS M KATHLEEN | Director | Stock Award(Grant) | Sep 29, 2024 | 406,515 |
| DECKER LISA LYNN | Officer | Sale | Dec 15, 2024 | 78,041 |
| HARLER MARY BETH | Chief Executive Officer | Sale | Dec 15, 2024 | 347,032 |
| LEE MICHAEL STEWART | Director | Stock Award(Grant) | Sep 29, 2024 | 9,322 |
| REDMILE GROUP, L.L.C. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Sep 29, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 12.01% | 4,092,310 | 26.64M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 11.78% | 4,014,259 | 26.13M | Sep 29, 2024 |
| Siren, L.L.C. | 9.77% | 3,330,422 | 21.68M | Sep 29, 2024 |
| Redmile Group, LLC | 9.02% | 3,072,478 | 20.00M | Sep 29, 2024 |
| Goldman Sachs Group Inc | 3.70% | 1,259,230 | 8.20M | Sep 29, 2024 |
| Blackrock Inc. | 2.64% | 899,921 | 5.86M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) New Horizons Fund | 5.77% | 1,966,446 | 12.80M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 2.49% | 849,754 | 5.53M | Sep 29, 2024 |
| Fidelity Select Portfolios - Biotechnology | 2.38% | 809,982 | 5.27M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.35% | 461,049 | 3.00M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.18% | 401,289 | 2.61M | Oct 30, 2024 |
| Price (T.Rowe) New Horizons Trust | 1.16% | 396,148 | 2.58M | Sep 29, 2024 |